Marker Therapeutics Shares Rise Premarket on Key FDA Designation
20 January 2022 - 10:51PM
Dow Jones News
By Colin Kellaher
Shares of Marker Therapeutics Inc. rose more than 10% in
premarket trading Thursday after the clinical-stage immuno-oncology
company said the U.S. Food and Drug Administration granted
orphan-drug designation to its MT-601 T-cell therapy for the
treatment of pancreatic cancer.
The FDA's orphan-drug program gives special status to drugs and
biologics for diseases and disorders that affect fewer than 200,000
people in the U.S. and provides for an extended
marketing-exclusivity period against competition.
Houston-based Marker said MT-601 is its second multi-antigen
targeted T-cell therapy to receive the designation, and its first
in a solid tumor indication.
Marker shares, which closed Wednesday at 84 cents, were recently
up 11.7% to 94 cents in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 20, 2022 06:36 ET (11:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2024 to May 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From May 2023 to May 2024